A Mayo Clinic study has found that imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans. "These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some patients in our clinical ...
Read More
No comments:
Post a Comment